Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
about
Identification of DNA-PKcs as a primary resistance factor of TIC10 in hepatocellular carcinoma cells.Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathwayFirst-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer AgentSmall Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study.TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation.ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases.Discovery and clinical introduction of first-in-class imipridone ONC201.FOXO transcription factors in cancer development and therapy.Neuro-oncology biotech industry progress report.Negative regulation of the FOXO3a transcription factor by mTORC2 induces a pro-survival response following exposure to ultraviolet-B irradiation.ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.Molecular signaling cascades involved in nonmelanoma skin carcinogenesis.Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumorsThe Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma.Imipridone family on successful TRAIL.Breast cancer suppression by aplysin is associated with inhibition of PI3K/AKT/FOXO3a pathway.FoxO proteins or loss of functional p53 maintain stemness of glioblastoma stem cells and survival after ionizing radiation plus PI3K/mTOR inhibition.ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways.Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.MiR-629 promotes human pancreatic cancer progression by targeting FOXO3.FOXO3 induces ubiquitylation of AKT through MUL1 regulation.Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.Regulation of Akt/FoxO3a/Skp2 Axis Is Critically Involved in Berberine-Induced Cell Cycle Arrest in Hepatocellular Carcinoma Cells.Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor.Developing TRAIL/TRAIL death receptor-based cancer therapies.B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway.Cancer Stem Cells are Regulated by STAT3 Signalling in Wilms Tumour.ONC201: a new treatment option being tested clinically for recurrent glioblastomaFerrocene-Containing Impiridone (ONC201) Hybrids: Synthesis, DFT Modelling, In Vitro Evaluation, and Structure⁻Activity Relationships
P2860
Q33709701-26679D59-9770-4041-80FC-7C26C79B5D48Q35595688-BD221CC8-C8CA-4137-852F-4F89699DA14BQ35844988-8E6B600D-8CEC-4815-BA63-6131260FBA76Q36132383-7775E96F-3925-478B-A64D-2A77F803F5D1Q36546689-6EEB4F3D-4476-4B8B-A633-4D9B666A8300Q36748678-C245C4CD-D621-4059-8E0E-F6489F48E0D7Q36771879-57836D00-E0C8-4C49-8F37-111D1EE4AEC2Q37141946-A7343183-294C-45AE-9ACE-16FABD670130Q37687570-CDF7747F-3475-4420-9827-BC2FF108DFD3Q38674456-340B9233-6DC2-4C07-89FE-B6570C6F0696Q38741932-54D1408B-AF57-4F56-8499-B3AB422E4B25Q38779851-7BE4A345-4790-4D3F-A000-E81D6FA5EA13Q38829723-27AE0303-1648-4E26-9FC8-21E1E70F9F89Q38868990-01515705-3C5E-4455-9DE8-96FD823E90A6Q38966698-A5D755DE-FF52-4A8E-8351-03E219E798CAQ41212464-0EE4FDB2-09D4-4814-9CA6-D3FF9FCFA266Q41566564-CE8BBECF-7CA5-401B-9EA1-EACC627F7781Q41617112-19EC9AE1-EAAD-4B07-BFA5-A723EF7DB85EQ41907536-8ECD1A42-63EE-4EE7-8F00-DF18E118E16CQ42317507-22611AEA-DB11-403E-A92D-C7DB07836771Q42365296-8931A6AF-9AFB-4949-A28C-32470A3C35C8Q42709967-9BCA4CEE-155F-489B-B121-A98947E75C19Q45559181-5D419A97-78CB-4D46-80F8-CB4A6E04F2BDQ46037722-57695922-917F-4F63-B1C4-68AD1BDF8BF3Q47105200-6C31335B-D171-4FDB-B55D-E4A245B2E28DQ48163220-60ACC26B-A7BD-4F6C-8F35-BE00408A5AB8Q48184827-C2E82A6C-5EA3-46CB-A9EE-7167D514632DQ48192170-4925B0FD-BFE0-4009-9742-BEEEB376179FQ50204389-40624981-3369-4E65-A2F6-64879617684EQ52658085-76448125-000A-4A0C-8F23-23CD7EA88681Q52720988-DF091162-AAC2-484E-BD56-D4CE64859FE4Q53701901-0438C30D-5967-4EB4-BE99-0C782D945E0EQ53800920-A5C92EDA-7D2A-4CA1-9E10-71102059DCBEQ55254109-E1580F77-04A0-49D2-BCED-188DFB406CADQ55980927-7185E87D-D9DB-4E11-8ADE-724E47617A2AQ58696201-78B0FF13-5411-4BEB-8F2F-E2B71AE17A0E
P2860
Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Small-Molecule ONC201/TIC10 Ta ...... Foxo3a/TRAIL-Dependent Manner.
@ast
Small-Molecule ONC201/TIC10 Ta ...... Foxo3a/TRAIL-Dependent Manner.
@en
type
label
Small-Molecule ONC201/TIC10 Ta ...... Foxo3a/TRAIL-Dependent Manner.
@ast
Small-Molecule ONC201/TIC10 Ta ...... Foxo3a/TRAIL-Dependent Manner.
@en
prefLabel
Small-Molecule ONC201/TIC10 Ta ...... Foxo3a/TRAIL-Dependent Manner.
@ast
Small-Molecule ONC201/TIC10 Ta ...... Foxo3a/TRAIL-Dependent Manner.
@en
P2093
P2860
P1433
P1476
Small-Molecule ONC201/TIC10 Ta ...... /Foxo3a/TRAIL-Dependent Manner
@en
P2093
David T Dicker
Joshua E Allen
Varun V Prabhu
P2860
P304
P356
10.1158/0008-5472.CAN-13-3451
P407
P577
2015-02-20T00:00:00Z